reports
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
UCB TRx noise aside, fundamentals remain strong
UCB's Bimzelx is well-positioned with strong 3-year data in HS and competitive performance across PsO, PsA, and axSpA, supporting our peak sales estimate of €5.9b by 2030. Despite premium forward P/E multiples, UCB's projected EPS CAGR (2025–2029), being >3x that of peers, means UCB continues to be an attractive name to own. Earlier in the pipeline, our deep dive into the atopic dermatitis (AD) landscape shows that phase 2a data for galovokimig is promising, with plans to advance to phase 2b. Ac...
IBA integrates Artificial Intelligence Quality Assurance into dosimetr...
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance. Found...
IBA intègre l’assurance qualité de l’intelligence artificielle dans se...
IBA intègre l’assurance qualité de l’intelligence artificielle dans ses solutions de dosimétrie grâce à l'acquisition de PhantomX GmbH Renforcement du portefeuille de Dosimetry avec l'assurance qualité en imagerie médicale et la validation par IA Louvain-la-Neuve, Belgique, le 3 novembre 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et l'un des principaux fournisseurs de solutions de dosimétrie et d'assurance qualité en radiothérapie et en imagerie médicale (QA), annonce aujourd'hui l'acquisition de PhantomX GmbH, élargis...
- ING Helpdesk
Benelux Morning Notes
AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
Participation notification by Morgan Stanley
Participation notification by Morgan Stanley Press release Regulated information Brussels, October 27, 2025, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold was crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total October 16, 2025 / / / The ...
Notification de participation par Morgan Stanley
Notification de participation par Morgan Stanley Communiqué de presse Information réglementée Bruxelles, le 27 octobre 2025 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), Morgan Stanley a envoyé récemment à Solvay la notification de transparence suivante, indiquant avoir franchi le seuil de 3%. Voici un résumé de la notification: Date à laquelle le seuil a été franchi Droits de vote après la transaction Instruments financiers équivalents après la tra...
Participatiemelding van Morgan Stanley
Participatiemelding van Morgan Stanley Persbericht Gereglementeerde informatie Brussel, 27 oktober 2025 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft Morgan Stanley onlangs de volgende transparantiekennisgeving naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de beweging: Datum van drempeloverschrijding Stemrechten na de transactie Aan stemrechten gelijkgestelde financiële instrumenten na de transactie Totaa...
- Jacob Mekhael
UCB Supportive 3-year data for Bimzelx in PsA and axSpA at ACR 2025
UCB announced new 3-year data for Bimzelx in adults with active psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) at ACR 2025. The results show sustained responses in both patient groups, and appear competitive vs. other biologics e.g. Cosentyx in cross-trial comparison. Overall supportive data that should maintain Bimzelx' commercial momentum. ACCUMULATE maintained.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
UCB SA: 1 director
A director at UCB SA bought 70 shares at 250.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
UPDATE ON FIXED INCOME INVESTOR MEETINGS
UPDATE ON FIXED INCOME INVESTOR MEETINGS Press release Antwerp, Oct. 23, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) references the stock exchange release dated 20 October 2025 regarding fixed income investor meetings. Following engagement with potential investors, CMB.TECH has decided not to proceed with the issue of a senior unsecured bond. The indicative terms offered under the current market conditions were less favourable compared to the other funding sources available to the Company. For further informat...
Participation notification by Morgan Stanley
Participation notification by Morgan Stanley Press release Regulated information Brussels, October 21, 2025, 17:45 CEST In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold was crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total October 14, 2025 0...
Notification de participation par Morgan Stanley
Notification de participation par Morgan Stanley Communiqué de presse Information réglementée Bruxelles, le 21 octobre 2025 - 17h45 CEST Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), Morgan Stanley a envoyé récemment à Solvay la notification de transparence suivante, indiquant avoir franchi le seuil de 3%. Voici un résumé de la notification: Date à laquelle le seuil a été franchi Droits de vote après la transaction Instruments financiers équivale...
Participatiemelding van Morgan Stanley
Participatiemelding van Morgan Stanley Persbericht Gereglementeerde informatie Brussel, 21 oktober 2025 - 17u45 CEST In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft Morgan Stanley onlangs de volgende transparantiekennisgeving naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de beweging: Datum van drempeloverschrijding Stemrechten na de transactie Aan stemrechten gelijkgestelde financiële instrumenten na de transactie ...
- Dominic Rose
- Naresh Chouhan
- Kristof Samoy
CMB.Tech Unscheduled 3Q25 trading update released
This morning CMB.TECH issued an update which went unnoticed due to technical issues. We presume the release has to do with the ongoing fixed income investor meetings to refinance (half of) the $1.4bn bridge loan taken out to acquire the stake in Golden Ocean. The update was limited to the publication of TCE rates and confirmed the rumoured sale of the VLCC Dalma (°2007) which resulted in a handsome $27m capital gain. The attractive rate fixtures in the 4Q25 more than make up for the shortfall in...
- Hilde Van Boxstael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
PRESS RELEASE: CMB.TECH NV announces fixed income investor meetings
PRESS RELEASE: CMB.TECH NV announces fixed income investor meetings Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) has mandated Danske Bank, DNB Carnegie, Nordea Bank and Pareto Securities to arrange a series of fixed income investor meetings commencing today, October 20, 2025. Following the investor meetings a USD denominated five-year senior unsecured bond issue may follow, subject to inter alia market conditions. The proceeds from the potential bond issue will be used for general corporate purp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.